Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | NRP1 | O14786 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.44 |
| ▸ | RAMP3 | O60896 | 4/20 | 0.44 |
| ▸ | CALCR | P30988 | 4/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24485881 | 1.00 | MAPK8 (0.46) | MAPK8MAPK9MAPK10CXCR4NRP1 | |
| SCHEMBL31188444 | 0.95 | NRP1 (0.48) | NRP1OPRM1OPRK1RAMP3CALCR | |
| SCHEMBL12237948 | 0.94 | CXCR4 (0.49) | MAPK8MAPK9MAPK10CXCR4OPRM1 | |
| SCHEMBL24485493 | 0.92 | F2 (0.49) | CXCR4NRP1OPRM1OPRK1F2 | |
| SCHEMBL11168724 | 0.91 | RAMP3 (0.48) | MAPK8MAPK9MAPK10OPRM1OPRK1 | |
| SCHEMBL11170849 | 0.91 | RAMP3 (0.48) | MAPK8MAPK9MAPK10OPRM1OPRK1 | |
| SCHEMBL11170810 | 0.91 | RAMP3 (0.48) | MAPK8MAPK9MAPK10OPRM1OPRK1 | |
| SCHEMBL9764520 | 0.91 | RAMP3 (0.48) | MAPK8MAPK9MAPK10OPRM1OPRK1 | |
| SCHEMBL11168683 | 0.91 | RAMP3 (0.48) | MAPK8MAPK9MAPK10OPRM1OPRK1 | |
| SCHEMBL9764553 | 0.91 | RAMP3 (0.48) | MAPK8MAPK9MAPK10OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590122-B2 | NRP-1 binding inhibitory peptides and uses thereof | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-03-31 | — | — | US | disclosed |
| US-20220169677-A1 | NRP-1 BINDING INHIBITORY PEPTIDES AND USES THEREOF | UNIVERSITÉ PARIS CITÉ (FR) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590122-B2 | NRP-1 binding inhibitory peptides and uses thereof | NRP1, FLT1, KDR | MAPK8 1864/4885MAPK9 3203/4885MAPK10 2495/4885 |
| US-20220169677-A1 | NRP-1 BINDING INHIBITORY PEPTIDES AND USES THEREOF | NRP1, KDR, FLT1 | MAPK8 1496/4885MAPK9 2802/4885MAPK10 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.